Grandidier will be responsible for the development, clinical study and commercialization of the company’s tissue-engineered heart valve technology.

Previously, he held various executive positions in Boston Scientific, Guidant and Teleflex Medical.

He also served at Endosense as vice president of sales and marketing.

Xeltis CEO Laurent Grandidier said the longevity and self-healing properties of Xeltis’ valves may not only open up new therapeutic options for a vastly underserved pediatric and young patient population but may also address the increasingly apparent shortcomings of all existing transcatheter valve solutions.